SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. and certain officers for alleged violations of federal securities laws during the Class Period from March 7, 2024, to May 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Savara securities during the specified Class Period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding the company's business and operations, particularly concerning the MOLBREEVI Biologics License Application (BLA) [3]. - Specific allegations include the lack of sufficient information regarding MOLBREEVI's chemistry and manufacturing, the unlikelihood of FDA approval in its current form, and the potential need for Savara to raise additional capital due to delays in regulatory approval [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Savara have until November 7, 2025, to request appointment as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].